カテゴリー： QYResearch, 北米

アレルギー性鼻炎薬の米国市場

【英語タイトル】United States Allergic Rhinitis Drugs Market Research Report 2022

QYResearchが出版した調査資料（RG-022766-US）・商品コード：RG-022766-US
・発行会社（調査会社）：QYResearch
・発行日：2022年8月
・ページ数：約90
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：米国
・産業分野：製薬
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,400 ⇒換算￥496,400見積依頼/購入/質問フォーム
Multi User（5名様閲覧用）USD5,100 ⇒換算￥744,600見積依頼/購入/質問フォーム
Enterprise License（法人閲覧用）USD6,800 ⇒換算￥992,800見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

Due to the COVID-19 pandemic, the United States Allergic Rhinitis Drugs market size is estimated to be worth US$ xx million in 2022 and is forecast to a readjusted size of US$ xx million by 2028 with a CAGR of xx% during the review period. Fully considering the economic change by this health crisis, Antihistamines accounting for xx% of the Allergic Rhinitis Drugs United States market in 2021, is projected to value US$ xx million by 2028, growing at a revised xx% CAGR in the post-COVID-19 period. While Hospital Pharmacy segment is altered to an xx % CAGR throughout this forecast period.
In United States, the key manufacturers of Allergic Rhinitis Drugs include GlaxoSmithKline, Sanofi, ALK-Abelló, Meda Pharmaceuticals, Adamis Pharmaceuticals, Allergy Therapeutics, Almirall, Ampio, and AstraZeneca, etc. In 2021, the top five players have a share approximately XX% in terms of revenue.
Allergic Rhinitis Drugs market is segmented by Type, and by Application. Players, stakeholders, and other participants in the United States Allergic Rhinitis Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type, and by Application for the period 2017-2028.

Segment by Type
 Antihistamines
 Intranasal Corticosteroids
 Immunotherapies

Segment by Application
 Hospital Pharmacy
 Retail Pharmacy
 Online Pharmacy

By Company
 GlaxoSmithKline
 Sanofi
 ALK-Abelló
 Meda Pharmaceuticals
 Adamis Pharmaceuticals
 Allergy Therapeutics
 Almirall
 Ampio
 AstraZeneca
 Amneal Pharmaceuticals
 Anergis
 Apotex
 Array BioPharma
 Aspen Pharmacare
 Circassia Pharmaceuticals
 Dr Reddy’s Laboratories
 Eddingpharm
 EMS
 HAL Allergy
 Inmunotek
 Genentech
 Greer Laboratories
 Glenmark Pharmaceuticals
 Hanmi Pharmaceuticals
 Hisamitsu Pharmaceutical
 Intas Pharmaceuticals
 Novartis

❖ レポートの目次 ❖

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 United States Allergic Rhinitis Drugs Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Antihistamines
1.2.3 Intranasal Corticosteroids
1.2.4 Immunotherapies
1.3 Market by Application
1.3.1 United States Allergic Rhinitis Drugs Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Pharmacy
1.4 Study Objectives
1.5 Years Considered
2 United States Growth Trends
2.1 United States Allergic Rhinitis Drugs Market Perspective (2017-2028)
2.2 Allergic Rhinitis Drugs Market Dynamics
2.2.1 Allergic Rhinitis Drugs Industry Trends
2.2.2 Allergic Rhinitis Drugs Market Drivers
2.2.3 Allergic Rhinitis Drugs Market Challenges
2.2.4 Allergic Rhinitis Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 United States Allergic Rhinitis Drugs Revenue by Players
3.1.1 United States Allergic Rhinitis Drugs Revenue by Players (2017-2022)
3.1.2 United States Allergic Rhinitis Drugs Revenue Market Share by Players (2017-2022)
3.2 United States Allergic Rhinitis Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Allergic Rhinitis Drugs Revenue
3.4 United States Allergic Rhinitis Drugs Market Concentration Ratio
3.4.1 United States Allergic Rhinitis Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 United States Top 3 and Top 5 Companies by Allergic Rhinitis Drugs Revenue in 2021
3.5 Allergic Rhinitis Drugs Key Players Head office and Area Served
3.6 Key Players Allergic Rhinitis Drugs Product Solution and Service
3.7 Date of Enter into Allergic Rhinitis Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Allergic Rhinitis Drugs Breakdown Data by Type
4.1 United States Allergic Rhinitis Drugs Historic Market Size by Type (2017-2022)
4.2 United States Allergic Rhinitis Drugs Forecasted Market Size by Type (2023-2028)
5 Allergic Rhinitis Drugs Breakdown Data by Application
5.1 United States Allergic Rhinitis Drugs Historic Market Size by Application (2017-2022)
5.2 United States Allergic Rhinitis Drugs Forecasted Market Size by Application (2023-2028)
6 Key Players Profiles
6.1 GlaxoSmithKline
6.1.1 GlaxoSmithKline Company Details
6.1.2 GlaxoSmithKline Business Overview
6.1.3 GlaxoSmithKline Allergic Rhinitis Drugs Introduction
6.1.4 GlaxoSmithKline in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.1.5 GlaxoSmithKline Recent Development
6.2 Sanofi
6.2.1 Sanofi Company Details
6.2.2 Sanofi Business Overview
6.2.3 Sanofi Allergic Rhinitis Drugs Introduction
6.2.4 Sanofi in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.2.5 Sanofi Recent Development
6.3 ALK-Abelló
6.3.1 ALK-Abelló Company Details
6.3.2 ALK-Abelló Business Overview
6.3.3 ALK-Abelló Allergic Rhinitis Drugs Introduction
6.3.4 ALK-Abelló in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.3.5 ALK-Abelló Recent Development
6.4 Meda Pharmaceuticals
6.4.1 Meda Pharmaceuticals Company Details
6.4.2 Meda Pharmaceuticals Business Overview
6.4.3 Meda Pharmaceuticals Allergic Rhinitis Drugs Introduction
6.4.4 Meda Pharmaceuticals in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.4.5 Meda Pharmaceuticals Recent Development
6.5 Adamis Pharmaceuticals
6.5.1 Adamis Pharmaceuticals Company Details
6.5.2 Adamis Pharmaceuticals Business Overview
6.5.3 Adamis Pharmaceuticals Allergic Rhinitis Drugs Introduction
6.5.4 Adamis Pharmaceuticals in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.5.5 Adamis Pharmaceuticals Recent Development
6.6 Allergy Therapeutics
6.6.1 Allergy Therapeutics Company Details
6.6.2 Allergy Therapeutics Business Overview
6.6.3 Allergy Therapeutics Allergic Rhinitis Drugs Introduction
6.6.4 Allergy Therapeutics in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.6.5 Allergy Therapeutics Recent Development
6.7 Almirall
6.7.1 Almirall Company Details
6.7.2 Almirall Business Overview
6.7.3 Almirall Allergic Rhinitis Drugs Introduction
6.7.4 Almirall in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.7.5 Almirall Recent Development
6.8 Ampio
6.8.1 Ampio Company Details
6.8.2 Ampio Business Overview
6.8.3 Ampio Allergic Rhinitis Drugs Introduction
6.8.4 Ampio in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.8.5 Ampio Recent Development
6.9 AstraZeneca
6.9.1 AstraZeneca Company Details
6.9.2 AstraZeneca Business Overview
6.9.3 AstraZeneca Allergic Rhinitis Drugs Introduction
6.9.4 AstraZeneca in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.9.5 AstraZeneca Recent Development
6.10 Amneal Pharmaceuticals
6.10.1 Amneal Pharmaceuticals Company Details
6.10.2 Amneal Pharmaceuticals Business Overview
6.10.3 Amneal Pharmaceuticals Allergic Rhinitis Drugs Introduction
6.10.4 Amneal Pharmaceuticals in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.10.5 Amneal Pharmaceuticals Recent Development
6.11 Anergis
6.11.1 Anergis Company Details
6.11.2 Anergis Business Overview
6.11.3 Anergis Allergic Rhinitis Drugs Introduction
6.11.4 Anergis in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.11.5 Anergis Recent Development
6.12 Apotex
6.12.1 Apotex Company Details
6.12.2 Apotex Business Overview
6.12.3 Apotex Allergic Rhinitis Drugs Introduction
6.12.4 Apotex in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.12.5 Apotex Recent Development
6.13 Array BioPharma
6.13.1 Array BioPharma Company Details
6.13.2 Array BioPharma Business Overview
6.13.3 Array BioPharma Allergic Rhinitis Drugs Introduction
6.13.4 Array BioPharma in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.13.5 Array BioPharma Recent Development
6.14 Aspen Pharmacare
6.14.1 Aspen Pharmacare Company Details
6.14.2 Aspen Pharmacare Business Overview
6.14.3 Aspen Pharmacare Allergic Rhinitis Drugs Introduction
6.14.4 Aspen Pharmacare in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.14.5 Aspen Pharmacare Recent Development
6.15 Circassia Pharmaceuticals
6.15.1 Circassia Pharmaceuticals Company Details
6.15.2 Circassia Pharmaceuticals Business Overview
6.15.3 Circassia Pharmaceuticals Allergic Rhinitis Drugs Introduction
6.15.4 Circassia Pharmaceuticals in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.15.5 Circassia Pharmaceuticals Recent Development
6.16 Dr Reddy’s Laboratories
6.16.1 Dr Reddy’s Laboratories Company Details
6.16.2 Dr Reddy’s Laboratories Business Overview
6.16.3 Dr Reddy’s Laboratories Allergic Rhinitis Drugs Introduction
6.16.4 Dr Reddy’s Laboratories in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.16.5 Dr Reddy’s Laboratories Recent Development
6.17 Eddingpharm
6.17.1 Eddingpharm Company Details
6.17.2 Eddingpharm Business Overview
6.17.3 Eddingpharm Allergic Rhinitis Drugs Introduction
6.17.4 Eddingpharm in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.17.5 Eddingpharm Recent Development
6.18 EMS
6.18.1 EMS Company Details
6.18.2 EMS Business Overview
6.18.3 EMS Allergic Rhinitis Drugs Introduction
6.18.4 EMS in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.18.5 EMS Recent Development
6.19 HAL Allergy
6.19.1 HAL Allergy Company Details
6.19.2 HAL Allergy Business Overview
6.19.3 HAL Allergy Allergic Rhinitis Drugs Introduction
6.19.4 HAL Allergy in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.19.5 HAL Allergy Recent Development
6.20 Inmunotek
6.20.1 Inmunotek Company Details
6.20.2 Inmunotek Business Overview
6.20.3 Inmunotek Allergic Rhinitis Drugs Introduction
6.20.4 Inmunotek in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.20.5 Inmunotek Recent Development
6.21 Genentech
6.21.1 Genentech Company Details
6.21.2 Genentech Business Overview
6.21.3 Genentech Allergic Rhinitis Drugs Introduction
6.21.4 Genentech in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.21.5 Genentech Recent Development
6.22 Greer Laboratories
6.22.1 Greer Laboratories Company Details
6.22.2 Greer Laboratories Business Overview
6.22.3 Greer Laboratories Allergic Rhinitis Drugs Introduction
6.22.4 Greer Laboratories in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.22.5 Greer Laboratories Recent Development
6.23 Glenmark Pharmaceuticals
6.23.1 Glenmark Pharmaceuticals Company Details
6.23.2 Glenmark Pharmaceuticals Business Overview
6.23.3 Glenmark Pharmaceuticals Allergic Rhinitis Drugs Introduction
6.23.4 Glenmark Pharmaceuticals in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.23.5 Glenmark Pharmaceuticals Recent Development
6.24 Hanmi Pharmaceuticals
6.24.1 Hanmi Pharmaceuticals Company Details
6.24.2 Hanmi Pharmaceuticals Business Overview
6.24.3 Hanmi Pharmaceuticals Allergic Rhinitis Drugs Introduction
6.24.4 Hanmi Pharmaceuticals in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.24.5 Hanmi Pharmaceuticals Recent Development
6.25 Hisamitsu Pharmaceutical
6.25.1 Hisamitsu Pharmaceutical Company Details
6.25.2 Hisamitsu Pharmaceutical Business Overview
6.25.3 Hisamitsu Pharmaceutical Allergic Rhinitis Drugs Introduction
6.25.4 Hisamitsu Pharmaceutical in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.25.5 Hisamitsu Pharmaceutical Recent Development
6.26 Intas Pharmaceuticals
6.26.1 Intas Pharmaceuticals Company Details
6.26.2 Intas Pharmaceuticals Business Overview
6.26.3 Intas Pharmaceuticals Allergic Rhinitis Drugs Introduction
6.26.4 Intas Pharmaceuticals in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.26.5 Intas Pharmaceuticals Recent Development
6.27 Novartis
6.27.1 Novartis Company Details
6.27.2 Novartis Business Overview
6.27.3 Novartis Allergic Rhinitis Drugs Introduction
6.27.4 Novartis in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022)
6.27.5 Novartis Recent Development
7 Analyst’s Viewpoints/Conclusions
8 Appendix
8.1 Research Methodology
8.1.1 Methodology/Research Approach
8.1.2 Data Source
8.2 Disclaimer
8.3 Author Details

LIST OF TABLES
Table 1. United States Allergic Rhinitis Drugs Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Antihistamines
Table 3. Key Players of Intranasal Corticosteroids
Table 4. Key Players of Immunotherapies
Table 5. United States Allergic Rhinitis Drugs Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 6. Allergic Rhinitis Drugs Market Trends
Table 7. Allergic Rhinitis Drugs Market Drivers
Table 8. Allergic Rhinitis Drugs Market Challenges
Table 9. Allergic Rhinitis Drugs Market Restraints
Table 10. United States Allergic Rhinitis Drugs Revenue by Players (2017-2022) & (US$ Million)
Table 11. United States Allergic Rhinitis Drugs Market Share by Players (2017-2022)
Table 12. United States Top Allergic Rhinitis Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Allergic Rhinitis Drugs as of 2021)
Table 13. Ranking of United States Top Allergic Rhinitis Drugs Companies by Revenue (US$ Million) in 2021
Table 14. United States 5 Largest Players Market Share by Allergic Rhinitis Drugs Revenue (CR5 and HHI) & (2017-2022)
Table 15. Key Players Headquarters and Area Served
Table 16. Key Players Allergic Rhinitis Drugs Product Solution and Service
Table 17. Date of Enter into Allergic Rhinitis Drugs Market
Table 18. Mergers & Acquisitions, Expansion Plans
Table 19. United States Allergic Rhinitis Drugs Market Size by Type (2017-2022) & (US$ Million)
Table 20. United States Allergic Rhinitis Drugs Revenue Market Share by Type (2017-2022)
Table 21. United States Allergic Rhinitis Drugs Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 22. United States Allergic Rhinitis Drugs Revenue Market Share by Type (2023-2028)
Table 23. United States Allergic Rhinitis Drugs Market Size by Application (2017-2022) & (US$ Million)
Table 24. United States Allergic Rhinitis Drugs Revenue Market Share by Application (2017-2022)
Table 25. United States Allergic Rhinitis Drugs Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 26. United States Allergic Rhinitis Drugs Revenue Market Share by Application (2023-2028)
Table 27. GlaxoSmithKline Company Details
Table 28. GlaxoSmithKline Business Overview
Table 29. GlaxoSmithKline Allergic Rhinitis Drugs Product
Table 30. GlaxoSmithKline in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 31. GlaxoSmithKline Recent Development
Table 32. Sanofi Company Details
Table 33. Sanofi Business Overview
Table 34. Sanofi Allergic Rhinitis Drugs Product
Table 35. Sanofi in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 36. Sanofi Recent Development
Table 37. ALK-Abelló Company Details
Table 38. ALK-Abelló Business Overview
Table 39. ALK-Abelló Allergic Rhinitis Drugs Product
Table 40. ALK-Abelló in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 41. ALK-Abelló Recent Development
Table 42. Meda Pharmaceuticals Company Details
Table 43. Meda Pharmaceuticals Business Overview
Table 44. Meda Pharmaceuticals Allergic Rhinitis Drugs Product
Table 45. Meda Pharmaceuticals in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 46. Meda Pharmaceuticals Recent Development
Table 47. Adamis Pharmaceuticals Company Details
Table 48. Adamis Pharmaceuticals Business Overview
Table 49. Adamis Pharmaceuticals Allergic Rhinitis Drugs Product
Table 50. Adamis Pharmaceuticals in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 51. Adamis Pharmaceuticals Recent Development
Table 52. Allergy Therapeutics Company Details
Table 53. Allergy Therapeutics Business Overview
Table 54. Allergy Therapeutics Allergic Rhinitis Drugs Product
Table 55. Allergy Therapeutics in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 56. Allergy Therapeutics Recent Development
Table 57. Almirall Company Details
Table 58. Almirall Business Overview
Table 59. Almirall Allergic Rhinitis Drugs Product
Table 60. Almirall in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 61. Almirall Recent Development
Table 62. Ampio Company Details
Table 63. Ampio Business Overview
Table 64. Ampio Allergic Rhinitis Drugs Product
Table 65. Ampio in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 66. Ampio Recent Development
Table 67. AstraZeneca Company Details
Table 68. AstraZeneca Business Overview
Table 69. AstraZeneca Allergic Rhinitis Drugs Product
Table 70. AstraZeneca in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 71. AstraZeneca Recent Development
Table 72. Amneal Pharmaceuticals Company Details
Table 73. Amneal Pharmaceuticals Business Overview
Table 74. Amneal Pharmaceuticals Allergic Rhinitis Drugs Product
Table 75. Amneal Pharmaceuticals in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 76. Amneal Pharmaceuticals Recent Development
Table 77. Anergis Company Details
Table 78. Anergis Business Overview
Table 79. Anergis Allergic Rhinitis Drugs Product
Table 80. Anergis in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 81. Anergis Recent Development
Table 82. Apotex Company Details
Table 83. Apotex Business Overview
Table 84. Apotex Allergic Rhinitis Drugs Product
Table 85. Apotex in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 86. Apotex Recent Development
Table 87. Array BioPharma Company Details
Table 88. Array BioPharma Business Overview
Table 89. Array BioPharma Allergic Rhinitis Drugs Product
Table 90. Array BioPharma in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 91. Array BioPharma Recent Development
Table 92. Aspen Pharmacare Company Details
Table 93. Aspen Pharmacare Business Overview
Table 94. Aspen Pharmacare Allergic Rhinitis Drugs Product
Table 95. Aspen Pharmacare in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 96. Aspen Pharmacare Recent Development
Table 97. Circassia Pharmaceuticals Company Details
Table 98. Circassia Pharmaceuticals Business Overview
Table 99. Circassia Pharmaceuticals Allergic Rhinitis Drugs Product
Table 100. Circassia Pharmaceuticals in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 101. Circassia Pharmaceuticals Recent Development
Table 102. Dr Reddy’s Laboratories Company Details
Table 103. Dr Reddy’s Laboratories Business Overview
Table 104. Dr Reddy’s Laboratories Allergic Rhinitis Drugs Product
Table 105. Dr Reddy’s Laboratories in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 106. Dr Reddy’s Laboratories Recent Development
Table 107. Eddingpharm Company Details
Table 108. Eddingpharm Business Overview
Table 109. Eddingpharm Allergic Rhinitis Drugs Product
Table 110. Eddingpharm in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 111. Eddingpharm Recent Development
Table 112. EMS Company Details
Table 113. EMS Business Overview
Table 114. EMS Allergic Rhinitis Drugs Product
Table 115. EMS in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 116. EMS Recent Development
Table 117. HAL Allergy Company Details
Table 118. HAL Allergy Business Overview
Table 119. HAL Allergy Allergic Rhinitis Drugs Product
Table 120. HAL Allergy in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 121. HAL Allergy Recent Development
Table 122. Inmunotek Company Details
Table 123. Inmunotek Business Overview
Table 124. Inmunotek Allergic Rhinitis Drugs Product
Table 125. Inmunotek in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 126. Inmunotek Recent Development
Table 127. Genentech Company Details
Table 128. Genentech Business Overview
Table 129. Genentech Allergic Rhinitis Drugs Product
Table 130. Genentech in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 131. Genentech Recent Development
Table 132. Greer Laboratories Company Details
Table 133. Greer Laboratories Business Overview
Table 134. Greer Laboratories Allergic Rhinitis Drugs Product
Table 135. Greer Laboratories in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 136. Greer Laboratories Recent Development
Table 137. Glenmark Pharmaceuticals Company Details
Table 138. Glenmark Pharmaceuticals Business Overview
Table 139. Glenmark Pharmaceuticals Allergic Rhinitis Drugs Product
Table 140. Glenmark Pharmaceuticals in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 141. Glenmark Pharmaceuticals Recent Development
Table 142. Hanmi Pharmaceuticals Company Details
Table 143. Hanmi Pharmaceuticals Business Overview
Table 144. Hanmi Pharmaceuticals Allergic Rhinitis Drugs Product
Table 145. Hanmi Pharmaceuticals in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 146. Hanmi Pharmaceuticals Recent Development
Table 147. Hisamitsu Pharmaceutical Company Details
Table 148. Hisamitsu Pharmaceutical Business Overview
Table 149. Hisamitsu Pharmaceutical Allergic Rhinitis Drugs Product
Table 150. Hisamitsu Pharmaceutical in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 151. Hisamitsu Pharmaceutical Recent Development
Table 152. Intas Pharmaceuticals Company Details
Table 153. Intas Pharmaceuticals Business Overview
Table 154. Intas Pharmaceuticals Allergic Rhinitis Drugs Product
Table 155. Intas Pharmaceuticals in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 156. Intas Pharmaceuticals Recent Development
Table 157. Novartis Company Details
Table 158. Novartis Business Overview
Table 159. Novartis Allergic Rhinitis Drugs Product
Table 160. Novartis in United States: Revenue in Allergic Rhinitis Drugs Business (2017-2022) & (US$ Million)
Table 161. Novartis Recent Development
Table 162. Research Programs/Design for This Report
Table 163. Key Data Information from Secondary Sources
Table 164. Key Data Information from Primary Sources



★調査レポート[アレルギー性鼻炎薬の米国市場] (コード：RG-022766-US)販売に関する免責事項を必ずご確認ください。
★調査レポート[アレルギー性鼻炎薬の米国市場]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の便秘治療薬市場
  • 薬物乱用検査装置のアジア市場
  • ミカファンギンの米国市場
  • United States Plastic Food Container Market Research Report 2022
  • アメリカの分析機器市場2022
  • 世界の地震計市場
  • 核型解析の世界市場2022
  • 世界のNMP（N-メチル-2-ピロリドン）市場 2022年
  • 世界のコリン塩基市場
  • 世界の感圧紙市場

    • ◆H&Iグローバルリサーチのお客様（例）◆